ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 7,414 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the sale, the chief operating officer now directly owns 825,206 shares in the company, valued at approximately $54,735,913.98. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total transaction of $622,608.00.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total transaction of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total transaction of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total transaction of $541,055.20.

ANI Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ ANIP opened at $65.48 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $36.99 and a 1 year high of $70.81. The stock has a market cap of $1.38 billion, a P/E ratio of 77.95 and a beta of 0.79. The firm has a 50-day moving average of $64.60 and a 200 day moving average of $58.52. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. New York State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 0.9% during the 3rd quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after acquiring an additional 200 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in ANI Pharmaceuticals by 5.4% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 3,881 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 200 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of ANI Pharmaceuticals by 4.3% in the third quarter. The Manufacturers Life Insurance Company now owns 5,435 shares of the specialty pharmaceutical company’s stock worth $316,000 after acquiring an additional 225 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 248 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of ANI Pharmaceuticals by 60.0% in the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 291 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.